Product Highlight - Amgevita

Backed by Amgen’s 40 years of experience in biologics, the first adalimumab biosimilar approved in Hong Kong¹

• Proven clinical similarity to RP* adalimumab in 2 phase III studies^2,3

• Demonstrated similar Safety and Immunogenicity profile to RP in Head-to-Head studies^2,3

• Citrate-free formulation⁴


Also available in pre-filled syringe
*RP: reference product


References:
1. Department of Health. Drug Office [Online]. Available at: www.drugoffice.gov.hk/eps/do/en/healthcare_providers/home.html.
2. Cohen S, Genovese MC, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis 2017; 76(10): 1679-1687.
3. Papp K, Bachelez H, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol 2017; 76(6): 1093-1102.
4. Amgevita HK prescribing information [version: May 2020].